- Oops!Something went wrong.Please try again later.
Boston, Massachusetts--(Newsfile Corp. - April 6, 2021) - Block & Leviton is investigating whether FibroGen, Inc. (NASDAQ: FGEN) committed violations of securities fraud, and investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/fgen.
What is this all about?
After the markets closed, FibroGen admitted that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. The company said it would conduct a "comprehensive internal review to ensure" that such errors do not occur again. In after hours trading, FibroGen's shares are plunging by over 25%.
Who is eligible?
FibroGen shares are trading at below $25 per share in after-hours trading. Investors who have lost money on their FibroGen investment - - whether or not they have sold that investment - - are potentially eligible and should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is considering filing a securities class action lawsuit to attempt to recover losses on behalf of investors who have lost money.
What should I do next?
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at email@example.com, or by phone at (617) 398-5600.
Why should I contact Block & Leviton?
Many law firms have issued releases about this matter; many of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email firstname.lastname@example.org with any questions.
This notice may constitute attorney advertising.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/79609